E-LIB Suche - Ergebnisse für: Papadimitrakopoulou, Vassiliki A.

1

Brief Report: Safety and Antitumor Activity of Durvalumab P..:

Garon, Edward B. ; Spira, Alexander I. ; Goldberg, Sarah B....
Journal of Thoracic Oncology. 18 (2023) 8 - p. 1094-1102 , 2023

Link: https://doi.org/10.1016/..

2

Spatial PD‐L1, immune‐cell microenvironment, and genomic co..:

William Jr., William N. ; Zhang, Jianjun ; Zhao, Xin...
Cancer. 129 (2023) 5 - p. 714-727 , 2023

Link: https://doi.org/10.1002/..

3

Vidutolimod in Combination With Atezolizumab With and Witho..:

Negrao, Marcelo V. ; Papadimitrakopoulou, Vassiliki A. ; Price, Andrew C....
JTO Clinical and Research Reports. 4 (2023) 3 - p. 100423 , 2023

Link: https://doi.org/10.1016/..

4

Analysis of acquired resistance mechanisms to osimertinib i..:

Chmielecki, Juliann ; Mok, Tony ; Wu, Yi-Long...
Nature Communications. 14 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

5

Deep learning‐based pathology image analysis predicts cance..:

Zhang, Xinyi ; Gleber‐Netto, Frederico O. ; Wang, Shidan...
Cancer Medicine. 12 (2023) 6 - p. 7508-7518 , 2023

Link: https://doi.org/10.1002/..

6

Quality-of-life outcomes and risk prediction for patients r..:

Unger, Joseph M ; Qian, Lu ; Redman, Mary W...
JNCI: Journal of the National Cancer Institute. 115 (2023) 4 - p. 437-446 , 2023

Link: https://doi.org/10.1093/..

7

Clinical Outcomes for Plasma-Based Comprehensive Genomic Pr..:

Page, Ray D. ; Drusbosky, Leylah M. ; Dada, Hiba...
Clinical Lung Cancer. 23 (2022) 1 - p. 72-81 , 2022

Link: https://doi.org/10.1016/..

8

MTAP deficiency creates an exploitable target for antifolat..:

Alhalabi, Omar ; Chen, Jianfeng ; Zhang, Yuxue...
Nature Communications. 13 (2022) 1 - p. , 2022

Link: https://doi.org/10.1038/..

9

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab f..:

Borghaei, Hossein ; Redman, Mary W. ; Kelly, Karen...
Clinical Lung Cancer. 22 (2021) 3 - p. 178-186 , 2021

Link: https://doi.org/10.1016/..

10

A Phase II Study of Telisotuzumab Vedotin in Patients With ..:

Waqar, Saiama N. ; Redman, Mary W. ; Arnold, Susanne M....
Clinical Lung Cancer. 22 (2021) 3 - p. 170-177 , 2021

Link: https://doi.org/10.1016/..

11

Age Is Just a Number: Considerations for Older Adults in Ca..:

Habr, Dany ; McRoy, Lynn ; Papadimitrakopoulou, Vassiliki A
JNCI: Journal of the National Cancer Institute. 113 (2021) 11 - p. 1460-1464 , 2021

Link: https://doi.org/10.1093/..

12

Oncogene-specific differences in tumor mutational burden, P..:

Negrao, Marcelo V ; Skoulidis, Ferdinandos ; Montesion, Meagan...
Journal for ImmunoTherapy of Cancer. 9 (2021) 8 - p. e002891 , 2021

Link: https://doi.org/10.1136/..

13

Phase II study of durvalumab plus tremelimumab as therapy f..:

Leighl, Natasha B ; Redman, Mary W ; Rizvi, Naiyer...
Journal for ImmunoTherapy of Cancer. 9 (2021) 8 - p. e002973 , 2021

Link: https://doi.org/10.1136/..

14

Phase 2 Study of Talazoparib in Patients With Homologous Re..:

Owonikoko, Taofeek K. ; Redman, Mary W. ; Byers, Lauren A....
Clinical Lung Cancer. 22 (2021) 3 - p. 187-194.e1 , 2021

Link: https://doi.org/10.1016/..

15

Defining tumor resistance to PD-1 pathway blockade: recomme..:

Kluger, Harriet M. ; Tawbi, Hussein A. ; Ascierto, Maria L....
Journal for ImmunoTherapy of Cancer. 8 (2020) 1 - p. e000398 , 2020

Link: https://doi.org/10.1136/..